|
1
|
Oku K, Hamijoyo L, Kasitanon N, Li MT, Navarra S, Morand E, Tanaka Y, Mok CC. Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. Int J Rheum Dis 2021; 24:880-895. [PMID: 33999518 DOI: 10.1111/1756-185x.14125] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2021] [Accepted: 04/18/2021] [Indexed: 12/28/2022]
Abstract
Systemic lupus erythematosus (SLE) is a more common autoimmune rheumatic disease in the Asia-Pacific region. The prognosis of SLE remains unsatisfactory in some Asian countries because of delayed diagnosis, limited access to medications, increased complications and issues of tolerability and adherence to treatment. The Asia-Pacific League of Associations for Rheumatology SLE special interest group has recently published a set of consensus recommendations on the management of SLE for specialists, family physicians, specialty nurses, and other healthcare professionals in the Asia-Pacific region. This article reports a systematic literature review of the infective complications of SLE in Asia and evidence for prevention of these infections by pre-emptive antimicrobial therapy and vaccination.
Collapse
Affiliation(s)
- Kenji Oku
- Department of Rheumatology, Endocrinology and Nephrology Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Laniyati Hamijoyo
- Rheumatology Division, Department of Internal Medicine, Padjadjaran University, Bandung, Indonesia
| | - Nuntana Kasitanon
- Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Meng Tao Li
- Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, China.,National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, China
| | - Sandra Navarra
- Section of Rheumatology, University of Santo Tomas Hospital, Manila, Philippines
| | - Eric Morand
- Centre for Inflammatory Diseases, Monash University School of Clinical Sciences, Monash Medical Centre, Melbourne, Vic., Australia
| | - Yoshiya Tanaka
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Chi Chiu Mok
- Division of Rheumatology, Department of Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
| |
Collapse
|
|
2
|
Ruan L, Zhang Y, Luo Y, Yu X, Zeng Y, Peng H, Han L, Chen L, Roy S, Cheng Q, Li H, Guo X, Xiong D, Gan H, Liu M. Clinical features and outcomes of four HIV patients with COVID-19 in Wuhan, China. J Med Virol 2020; 93:133-136. [PMID: 32584483 PMCID: PMC7361640 DOI: 10.1002/jmv.26223] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2020] [Accepted: 06/23/2020] [Indexed: 12/15/2022]
Affiliation(s)
- Lianguo Ruan
- Department of Infectious Disease, Jinyintan Hospital, Wuhan, China
| | - Yan Zhang
- Department of Obstetrics and Gynecology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yanhe Luo
- Department of Infectious Disease, Jinyintan Hospital, Wuhan, China
| | - Xiaoli Yu
- Department of Infectious Disease, Jinyintan Hospital, Wuhan, China
| | - Yan Zeng
- Department of Infectious Disease, Jinyintan Hospital, Wuhan, China
| | - Hong Peng
- Department of Infectious Disease, Jinyintan Hospital, Wuhan, China
| | - Lijun Han
- Department of Infectious Disease, Jinyintan Hospital, Wuhan, China
| | - Lan Chen
- Department of Infectious Disease, Jinyintan Hospital, Wuhan, China
| | - Sankanika Roy
- Department of Stroke Medicine, Nottingham University Hospitals, Nottingham, UK
| | - Qiguang Cheng
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Huan Li
- Department of Radiology, Zhongnan Hospital, Wuhan University, Wuhan, China
| | - Xianfeng Guo
- Department of Orthopedic Surgery, Wuhan No. 7 Hospital, Wuhan, China
| | - Dexin Xiong
- Department of Thoracic Surgery, Hospital of Wuhan Red Cross Society, Wuhan, China
| | - Hui Gan
- Department of Allergy, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Mao Liu
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
|
3
|
Abstract
Pneumocystis jirovecii pneumonia (PcP) has for many years been reported mostly in human immunodeficiency virus-infected patients. Increasingly, it also affects other immunocompromised patients, e.g. after organ or allogeneic stem cell/bone marrow transplantation, patients with hematologic malignancies or autoimmune diseases. The diagnosis of PcP relies on a critical evaluation of clinical symptoms, risk factors, radiologic features and microbiological tests. High dose cotrimoxazole is the most effective therapeutic option. Rapid initiation is essential, since mortality is especially high in patients admitted to intensive care with respiratory failure. This article reviews the current epidemiology of PcP and highlights the diagnostic and therapeutic options. Recommendations for primary and secondary prophylaxis are summarized.
Collapse
|